Literature DB >> 11081151

Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.

I Shimon1, D Nass, M Hadani.   

Abstract

We report a case of acromegaly with relatively low GH secretion in a patient with GH-secreting pituitary macroadenoma. The 44-year-old male patient presented with left temporal hemianopsia and characteristic acromegalic face, but had relatively low baseline and post-glucose GH levels. IGF-1 and IGFBP-1 were elevated. Transsphenoidal surgery did not achieve clinical or biochemiacl remission, and the patient still had elevated IGF-1 levels with low GH. Histological examination of the resected tumor revealed a pituitary adenoma stained weakly for GH. The patient was treated then with monthly injections of Sandostatin-LAR, with clinical improvement and suppression of IGF-I to the normal range. This is a rare case of acromegaly without elevated GH levels, and good response to treatment with somatostatin analog, as expected in classical GH-secreting pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11081151     DOI: 10.1023/a:1009965201451

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  15 in total

1.  Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly.

Authors:  A L Barkan; I Halasz; K J Dornfeld; C A Jaffe; R D Friberg; W F Chandler; H M Sandler
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

Review 2.  Acromegaly.

Authors:  S Melmed
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

Review 3.  The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors.

Authors:  S W Lamberts
Journal:  Endocr Rev       Date:  1988-11       Impact factor: 19.871

4.  Inhibitory effect of octreotide on growth hormone-induced IGF-I generation and organ growth in hypophysectomized rats.

Authors:  A Flyvbjerg; K D Jørgensen; S M Marshall; H Orskov
Journal:  Am J Physiol       Date:  1991-04

5.  Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.

Authors:  P Caron; I Morange-Ramos; M Cogne; P Jaquet
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

6.  Sandostatin LAR in acromegalic patients: long-term treatment.

Authors:  A K Fløgstad; J Halse; S Bakke; I Lancranjan; P Marbach; C Bruns; J Jervell
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

7.  Acromegaly with 'normal' serum growth hormone levels. Clinical features, diagnosis and results of transsphenoidal microsurgery.

Authors:  S J Brockmeier; M Buchfelder; E F Adams; W Schott; R Fahlbusch
Journal:  Horm Metab Res       Date:  1992-08       Impact factor: 2.936

8.  Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy.

Authors:  M L Hartman; J D Veldhuis; M L Vance; A C Faria; R W Furlanetto; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

9.  Apparently silent somatotroph adenomas.

Authors:  P Pagesy; J Y Li; M Kujas; F Peillon; O Delalande; A Visot; P Derome
Journal:  Pathol Res Pract       Date:  1991-12       Impact factor: 3.250

10.  Investigation of the criteria for assessing the outcome of treatment in acromegaly.

Authors:  J Lindholm; B Giwercman; A Giwercman; J Astrup; P Bjerre; N E Skakkebaek
Journal:  Clin Endocrinol (Oxf)       Date:  1987-11       Impact factor: 3.478

View more
  4 in total

1.  Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity.

Authors:  Akiko Yoneda; Toshiaki Sano; Shozo Yamada; Abdulkader Obari; Zhi Rong Qian; Elaine Lu Wang; Naoko Inosita; Eiji Kudo
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

2.  Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage.

Authors:  John R Lindsay; Janet A Harding; Peter K Ellis; Brian Sheridan; A Brew Atkinson
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

3.  Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy.

Authors:  I Shimon; D Nass; D J Gross
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

4.  Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study.

Authors:  Giulia Carosi; Alessandra Mangone; Elisa Sala; Giulia Del Sindaco; Roberta Mungari; Arianna Cremaschi; Emanuele Ferrante; Maura Arosio; Giovanna Mantovani
Journal:  Eur J Endocrinol       Date:  2021-07-01       Impact factor: 6.664

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.